초록 ▼

The present invention provides compositions and methods for administering florfenicol to mammals. The compositions contain a prodrug of florfenicol in a pharmaceutically acceptable carrier. In one embodiment the prodrug is an esterized form of florfenicol. Examples of suitable prodrugs include one o

The present invention provides compositions and methods for administering florfenicol to mammals. The compositions contain a prodrug of florfenicol in a pharmaceutically acceptable carrier. In one embodiment the prodrug is an esterized form of florfenicol. Examples of suitable prodrugs include one or a combination of one or a combination of the following: florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate. In another embodiment the prodrug is converted into the florfenicol in vivo by the action of one or more endogenous esterases. The invention also provides new compounds, pharmaceutical compositions containing the compounds, and methods for their administration.

대표청구항 ▼

The invention claimed is: 1. A composition comprising florfenicol butyrate and a pharmaceutically acceptable solvent selected from N-methyl pyrrolidone, pyrrolidone, polyethylene glycol, propylene glycol, glycerol formal, isosorbid dimethyl ether, ethanol, dimethyl sulfoxide, tetrahydrofurfuryl alc

The invention claimed is: 1. A composition comprising florfenicol butyrate and a pharmaceutically acceptable solvent selected from N-methyl pyrrolidone, pyrrolidone, polyethylene glycol, propylene glycol, glycerol formal, isosorbid dimethyl ether, ethanol, dimethyl sulfoxide, tetrahydrofurfuryl alcohol, triacetin, and combinations thereof, wherein the composition is formulated as a composition for administration to a mammal by injection. 2. The composition of claim 1, wherein the solvent is selected from propylene glycol, glycerol formal, and combinations thereof. 3. The composition of claim 2, wherein the pharmaceutically acceptable solvent is a combination of propylene glycol and glycerol formal. 4. The composition of claim 1, wherein the concentration of florfenicol butyrate in the composition is at least about 200 mg/mL. 5. A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 1. 6. A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 2. 7. A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 3. 8. A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 4. 9. The pharmaceutical composition of claim 1, wherein the solvent is selected from the group consisting of propylene glycol, glycerol formal, N-methyl pyrrolidone, and combinations thereof. 10. The pharmaceutical composition of claim 9, wherein the solvent is a combination of propylene glycol, glycerol formal, and N-methyl pyrrolidone. 11. The pharmaceutical composition of claim 9, wherein the solvent is a combination of propylene glycol and N-methyl pyrrolidone. 12. The pharmaceutical composition of claim 9, wherein the solvent is a combination of glycerol formal and N-methyl pyrrolidone. 13. The pharmaceutical composition of claim 1, wherein the solvent is selected from the group consisting of tetrahydrofurfuryl alcohol, N-methyl pyrrolidone, and combinations thereof. 14. The pharmaceutical composition of claim 13, wherein the solvent is a combination of tetrahydrofurfuryl alcohol and N-methyl pyrrolidone. 15. The pharmaceutical composition of claim 1, wherein the solvent is selected from the group consisting of propylene glycol, glycerol formal, N-methyl pyrrolidone, polyethylene glycol, and combinations thereof. 16. The pharmaceutical composition of claim 15, wherein the solvent is a combination of polyethylene glycol and N-methyl pyrrolidone. 17. The pharmaceutical composition of claim 15, wherein the solvent is a combination of polyethylene glycol and glycerol formal. 18. The pharmaceutical composition of claim 15, wherein the solvent is a combination of polyethylene glycol and propylene glycol. 19. The pharmaceutical composition of claim 15, wherein the solvent is a combination of polyethylene glycol, propylene glycol, and N-methyl pyrrolidone.